Summary
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
Palisade Bio NASDAQ: PALI said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program.
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets
Palisade Bio offers a speculative early-stage opportunity, advancing PALI-2108, a gut-restricted PDE4 inhibitor for UC and Crohn's disease. PALI-2108's Phase 1 trials showed favorable safety, target engagement, and early clinical activity, supporting a differentiated mechanism of action. PALI's $132.6 million cash runway funds operations through key Phase 2 efficacy readouts in 2027–2028, reducing near-term dilution risk.
Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know
Palisade Bio (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Palisade Bio Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 16 | $35.68 | $20.16 | -$15.52 | -43.5% |
| BG Bart Gancher Intech Investment Management LLC | 31,153 | $69,471.19 | $39,720.07 | -$29,751.12 | -42.83% |
| KM Kristin Mariani Janus Henderson Group PLC | 10.54M | $24.82M | $13.54M | -$11.28M | -45.44% |
| CD Charlie Durham Sterling Capital Management LLC | 3,376 | $6,791.14 | $4,338.16 | -$2,452.98 | -36.12% |
| DRO Donal Reamonn O'Sullivan Brevan Howard Capital Management LP | 214,821 | $375,937.01 | $274,970.88 | -$100,966.13 | -26.86% |
Palisade Bio Inc. (PALI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Palisade Bio Inc. ever had a stock split?
Palisade Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | J. D. Finley CEO | NASDAQ (CM) Exchange | 696389402 CUSIP |
| US Country | 14 Employees | 18 Jul 2019 Last Dividend | 8 Apr 2024 Last Split | 20 Dec 2006 IPO Date |
Overview
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company based in Carlsbad, California, focused on developing innovative therapeutics designed to protect the integrity of the intestinal barrier. Their efforts are rooted in addressing medical conditions related to the digestive system, with an emphasis on improving postoperative recovery processes and minimizing complications stemming from surgeries. The company collaborates closely with key academic institutions and industry partners, such as the Regents of the University of California and Newsoara Biopharma Co., Ltd., to advance their research and development objectives. Through these strategic partnerships, Palisade Bio, Inc. aims to bring groundbreaking treatments to market that can significantly enhance patient outcomes in the United States.
Products and Services
- LB1148
Palisade Bio's flagship product, LB1148, represents a pioneering therapeutic approach in the realm of gastrointestinal surgery recovery. It is an oral liquid formulation of the enzyme inhibitor tranexamic acid, specifically designed to mitigate the formation of postoperative adhesions and accelerate the return of bowel function in adults following surgery. By targeting the digestive process, LB1148 not only aims to reduce the occurrence of postoperative ileus—a common and debilitating complication after abdominal surgery—but also facilitates a quicker and more comfortable recovery for patients. This product underscores Palisade Bio's commitment to improving surgical outcomes and patient quality of life through innovative biopharmaceutical solutions.
Contact Information
